ArticleBMC public health2025
Maternal vaccine delivery costs in South Asian settings: estimates from Bangladesh and Nepal.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral maternal vaccines are in clinical development. Maternal respiratory syncytial virus (RSV) vaccine has been introduced in several high and upper middle-income countries. With the recent World Health Organization (WHO) RSV prevention recommendation and Gavi, the Vaccine Alliance's commitment to open a funding window for RSV maternal vaccine programs, the vaccine will soon be available for low- and middle-income markets. Understanding costs of implementing new maternal vaccines within existing health systems in low-and middle-income countries (LMICs) is critical to inform introduction decisions. This study projects the cost of maternal immunization (MI) introduction and delivery in Bangladesh and Nepal.
methodsUsing an activity based prospective costing approach, we project MI introduction and delivery costs for a five-year period in each country. In-country stakeholders informed the future MI delivery strategies used for costing. Interviews with immunization and maternal health program representatives informed activities and resource needs. Primary data from a sample of sub-national health administrative units including vaccine stores and health facilities also informed anticipated MI operational costs. Financial and economic costs to the health system are estimated and reported in 2023 US$ units.
resultsStakeholders confirmed utilizing existing maternal tetanus vaccine delivery systems as the most feasible strategy for future MI delivery in both countries. The non-vaccine cost of delivering one dose of maternal vaccine was estimated at $0.45 and $1.81 (financial) and $2.01 and $4.49 (economic) in Bangladesh and Nepal, respectively. Excluding commodity cost, health worker training and demand generation activities were among the largest cost drivers in both countries. Relatively lower unit costs in Bangladesh are partly due to larger target population size leading to some efficiency in introduction costs. The anticipated coverage and baseline health system capacity gaps also contribute to the variation in unit costs between countries.
conclusionsMI delivery costs in LMICs are little known and this study contributes to filling this gap. These cost projections can equip countries to make informed introduction decisions as they evaluate the affordability and sustainability of MI programs in respective countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.